At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 151 enrolled
Drug / intervention
Lenvatinib +1 moredrug
Likely dose
Lenvatinib 24 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Three-Cohort, Phase 2 Study of E7080 (Lenvatinib) in Subjects With Recurrent Malignant Glioma
In Brief
A Phase 2 clinical trial evaluating Lenvatinib and Bevacizumab for Glioma. Completed, enrolled 151 participants across 5 sites in 2 countries.
Detailed Summary
An open-label phase 2, multicenter study in participants with recurrent malignant glioma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioma
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartNov 2010
Primary CompletionMar 2013
Study CompletionOct 2014
TodayJul 2026
First PostedJun 4, 2010
Enrollment StartNov 9, 2010
Primary CompletionMar 19, 2013
Study CompletionOct 28, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.1 years ago
Interventions
Lenvatinibdrug
24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
Bevacizumabdrug
Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.